Sheng Ding’s lab reports today in Cell Stem Cell (you can read it here) that they have replaced all genetic factors in a new iPS cell reprogramming method except Oct4. The other factors were replaced by chemical compounds. Thus, we continue a major transition in the iPS cell field away from genes and toward chemicals. […]
From genes to chemicals: iPS cell field, reprogramming in transition Read More »
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to
Challenges translating stem cell treatments to patients Read More »
The trouble with the risk of teratoma presents a stem cell paradox. Stem cells possess two traits lacking in other cells: self-renewal and pluripotency. This duo of defining functions is key to the ability of stem cells to be used to treat patients via regenerative medicine. A paradox exists because while self-renewal and pluripotency are both
The trouble with teratoma: a stem cell paradox Read More »
Cancer is a class of diseases that are intimately linked to stem cells. In fact, I would go so far as to call some types of cancer cells and stem cells, cousins. This concept, of a tight relationship between stem and cancer cells, is under intense investigation but at the same time it is something
Disease Focus Series: Cancer Read More »
It has been an eventful year so far for the stem cell field. Where do we go from here ? What are the key questions that face the field? Below are my top 10 questions for the field, NOT listed in any particular order, and some predictions. Update: you can see the predictions for the
Questions & my predictions for the stem cell field right now Read More »
CIRM Board Member, Jeff Sheehy, has a wonderful piece in Nature Medicine on why patient advocates play a critical role in decision making on research priorities (hat tip to Amy Adams who first blogged on Sheehy’s piece). Patient advocates bring a unique and valuable perspective to the table. Their role in guiding CIRM research funding
Why scientists must be advocates too: Jeff Sheehy Read More »
The severe spinal cord injury sustained by Jockey Michael Martinez and the possibility (not realized) that he might be enrolled in Geron’s hESC-based spinal cord regenerative medicine trial, have drawn recent attention to spinal cord injury. Christopher and Dana Reeve (see foundation here) as well as Don C. Reed (see site here) were instrumental in bringing
Stem cells for Spinal Cord Injury update Read More »
In Lewis Carroll’s masterpiece, Alice in Wonderland, there is a wonderful passage that came to mind as I read the latest response from the self-proclaimed ‘adult stem cell researchers’ suing the government to stop federally-funded ES cell research: “I don’t know what you mean by ‘glory,’ ” Alice said. Humpty Dumpty smiled contemptuously. “Of course you
Stem Cells in Wonderland Read More »
About one in ten people around the world will develop osteoarthritis (OA) at some point in their lives. In the U.S., it is the major cause of disability. This is an extremely serious illness in terms of its impact on society. At this time there is little in the way of effective treatments for OA.
Osteoarthritis stem cell research moving forward Read More »
We live in a plastic world, full of BPA. Over the last 1/2 century, the proportion of our food and beverages that are consumed out of plastic containers has skyrocketed. Unfortunately, the concentrations of plastic-related chemicals in people around the world, even in remote corners, has gone up in parallel. I’ve written about avoiding plastic
Keep Your Stem Cells Away From BPA Read More »